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          Abstract                                                                                                                                  
Background. The clinical course of Idiopathic Membranous Nephropathy 
(IMN) varies from spontaneous remission of nephrotic syndrome (NS) to 
end-stage renal disease (ESRD). Selecting patients with high risk of 
progression for immunosuppressive therapy is mandatory. 
Methods. 86 IMN subjects were followed for median of 69 months (range 
6-253). Receiver operating characteristic curve and Cox proportional 
hazard model were used to evaluate prognostic factors for progression, 
defined as ESRD or eGFR reduction ≥50% of baseline. 
Results.  Among all, 24 subjects had progression. Area under the ROC 
curve of N-acetyl-β-glucosaminidase/creatinine ratio (NAG/C) were 
significantly higher than proteinuria/day (0.770 and 0.637 respectively, 
p=0.018). In multivariable Cox proportional hazard regression analysis, 
NAG/C and eGFR were independent predictors of progression. Compared 
to lowest tertile of NAG/C (<9.4 UI/gC) or highest tertile of eGFR (≥88 
ml/min/1.73m2), the hazard ratio of highest tertile of NAG/C (≥19.2) was 
18.97 (95%CI, 1.70-211.86) and lowest tertile of eGFR (<59) was 11.58 
(95%CI, 2.02-66.29). Subjects with high NAG/C or low eGFR  (high-risk, 
n.43) had increased progression rate compared to moderate to low NAG/C 
and high eGFR (low-risk, n.43) with or without NS at baseline (Log-rank 
test p=0.001 and 0.006, respectively). In NS subjects (n=65), in high-risk 
group progression rate was significantly higher (91% vs. 29%, p=0.003) 
and remission significantly lower (0% vs. 42%, p<0.001) in non-
immunosuppressed compared to steroids and cyclophosphamide treated 
patients; no significant differences were observed in low-risk group. 
Conclusions. IMN subjects with high NAG/C and low eGFR have 
increased risk of progression, and immunosuppressive treatment is 
suggested at diagnosis. 
 
             Introduction 
             In last decade great advances have been made in knowledge of 
pathophysiology and treatment of idiopathic membranous nephropathy 
(IMN). The discovery of podocyte antigen M-type phospholipase A2 
receptor [PLA(2)R] and its corresponding IgG autoantibodies confirmed 
the autoimmune nature of IMN (review in 1). Anti-PLA2R antibodies are 
present in 70-80% of IMN patients; their serum level correlates with 
degree of proteinuria and predict outcome, as high values are associated 
with low probability of spontaneous or treatment-induced remission (2-7). 
Prediction of progression evaluated in the third tertile of anti-PLA2R 
antibodies showed that the end point 25% serum creatinine (sCr) increase 
or sCr ≥1.30 mg/dL was 69% vs. 25% in the first tertile (8). However at 
present anti-PLA2R antibodies level do not exactly identify patients who 
will enter spontaneous remission and candidates to supportive therapy and 
patients at risk for progression which need immunosuppressive therapy at 
diagnosis.  Recently  Rituximab (RTX), the monoclonal antibody directed 
to podocyte  surface antigen CD20 of B cells, responsible of synthesis of 
anti- PLA(2)R autoantibodies, has been recognized as effective and safe 
treatment of IMN with nephrotic syndrome (NS) inducing remission in 
two-thirds of patients often unresponsive to other immunosuppressive 
agents (9-12). RTX, as more specific and safer treatment in comparison 
with non-specific agents often associated with serious adverse events, has 
been suggested as first-line therapy for IMN (13). RTX proposal as first-
line therapy in IMN with NS, characterized by about 30-40% of 
spontaneous remission, requires the availability of baseline risk 
stratification able to identify patients with high probability of spontaneous 
remission and long-lasting normal renal function (NRF) which should be 
treated with supportive therapy and patients with high risk of progression 
which need immunosuppressive treatment at diagnosis; thus such risk 
stratification could be of paramount importance for early therapeutic 
decisions and baseline selection of patients which should be treated or not 
with IS-therapy. Studies to determine biomarkers value to predict 
prognosis and treatment responsiveness are still needed (14). Thus the aim 
of the study was to assess the proteinuric and functional prognostic factors 
that allow risk stratification with such predictive value in a longitudinal 
study of 86 IMN patients with rather long follow-up.                                                                                                                    
             Patients  
             The study included 86 IMN patients diagnosed between January 
1992 and April 2006 at the Nephrology and Dialysis Unit of San Carlo 
Borromeo Hospital, Milan, Italy. Inclusion criteria: clinical presentation: 
persistent non-nephrotic proteinuria (PP, n = 14) or nephrotic syndrome 
(NS, n = 72: 24-hour proteinuria ≥3.5 g and/or serum albumin <3.0 g/dL); 
typical features at light and immunofluorescence microscopy; no clinical, 
imaging and laboratory signs of secondary MN; at least 6 glomeruli in 
renal biopsy. The study complied with the Declaration of Helsinki and the 
local requirements for ethical approval. All patients gave informed written 
consent. Baseline characteristics of patients are reported in Table 1.  
             Laboratory analysis and renal biopsies 
             Proteinuria was measured in 24 hour urine collection and in 
second morning urine sample by the Coomassie blue method (modified 
with sodium-dodecyl-sulphate) and expressed as 24 hour proteinuria and 
protein creatinine/ratio (mg urinary protein/g urinary creatinine). Serum 
(sCr) and urinary creatinine (uCr) were measured enzymatically and 
expressed in mg/dL. Serum and urinary IgG, α2-macroglobulin (α2m), 
albumin, transferrin and α1-microglobulin (α1m) were measured by 
immunonephelometry as described ; N-acetyl-β-glucosaminidase (NAG) 
was measured by colorimetric method as described (16) and expressed as 
NAG/creatinine ratio (NAG/C). Glomerular filtration rate (eGFR) was 
estimated using the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) formula . Renal biopsies were performed and evaluated by 
previously described standard histological and immunofluorescence 
methods (18).   
             Follow up, treatment and outcome    
              A rather long follow up was available in all 86 patients (median 
69 months; range 6-268). Fourteen patients had PP and 72  NS; the 14  PP 
patients  were treated with supportive therapy; of them 9 had non-
nephrotic  proteinuria at biopsy that lowered over time; 5 patients had non-
nephrotic proteinuria at the first study of proteinuria  performed  sometime 
after renal biopsy and  a  previous history of  untreated  NS; 30 NS patients  
were treated with supportive therapy such as diuretics, anti-hypertensives 
(including ACEi [angiotensin converting enzyme inhibitor]/ARB 
[angiotensin II receptor blockers]), statins, anti-platelet agents, and vitamin 
D3 when indicated; 35 NS patients, besides supportive therapy, were 
treated at diagnosis with steroids and cyclophosphamide according to 
Ponticelli protocol (19); 7 NS patients were treated with steroids alone:  
prednisolone 1 mg/kg/day with tapering for 4–12 months (Fig. 1). The 
patients not lost to follow up were screened up until the last planned 
follow-up visit in 2015. 
The functional outcome evaluated after a rather long follow-up was very 
variable: we identified four different outcomes:                                                          
1) Clinical Remission [complete (proteinuria ≤ 0.20 g/24 hours), partial 
(proteinuria ≤ 2.0 g/24 hours)] with baseline and last NRF: n = 39 (n = 9 
with PP and NRF; n = 30 with NS and NRF); clinical remission in NS 
patients with baseline and last stable chronic renal failure (CRF): n = 7 
2)  Persistent nephrotic syndrome with baseline and last NRF: n = 8; 
3) Persistent nephrotic syndrome with eGFR reduction from 51±24 to 
39±11 ml/min/1.73m2 at last observation: n = 8; 
4)  Progression: end stage renal disease (ESRD) or eGFR reduction ≥50%: 
n = 24.  
             Statistical analysis 
              Continuous variables are expressed as means ± SD. Urinary 
markers were log-transformed before statistical analyses due to their 
skewed distribution, and expressed as geometric means (95% confidence 
interval). The renal function decline during the follow-up period was 
calculated by: eGFR change = [eGFR(last) - eGFR(1st)]/Follow-up × 12 
(ml/min/1.73m2/year). The change of proteinuria was calculated by: 
Proteinuria change = Proteinuria(last) – Proteinuria(1st) (g/24hr). The 
differences of median for continuous values between the study groups 
were determined using the Wilcoxon rank-sum test. Receiver Operating 
Characteristic (ROC) curve was plotted to determine the area under the 
curve (AUC) to compare the predictive ability of proteinuric markers to 
discriminate between progressors and non-progressors. Cox proportional 
hazard model was used to assess unadjusted and multivariable-adjusted 
hazard ratio on the population as a whole.  Kaplan-Meier curves and Log-
rank tests were used to compare progression or remission rate according to 
risk levels or treatment. Time of progression or remission was calculated 
from the date of diagnosis. Patients were censored at the time of renal 
death or at the end of follow-up. All statistical analyses were performed 
using Stata 12.1 (StataCorp LP, TX, USA). Two-sided p < 0.05 was 
considered statistically significant. 
              RESULTS                                                                                                                        
             ROC analysis of proteinuric markers  
Area under ROC curve (AUC) analysis to compare the predictive ability 
for progression was performed for all eight proteinuric markers (Fig. 2). 
Compared to proteinuria/24hr, UP/C, Alb/C, α1m/C, and NAG/C had 
significantly higher AUC (Table 2). After adjustment with age, sex, serum 
albumin, blood pressure, and ACEi/ARB treatment, hazard ratio (HR) of 
baseline eGFR and NAG/C were significant (Table 3). The multivariable-
adjusted HR for increase of eGFR was 0.96 (95% CI: 0.94, 0.98), and 
every 10-time increment of NAG/C was 20.98 (95% CI: 2.70, 162.69). 
Thus baseline eGFR and NAG/C were both independent markers for risk 
of progression.                  
              Functional outcome (progression, remission) according to 
tertiles of NAG/C in all 86 patients. 
                The progression rate in lowest (NAG/C <9.4, n = 28), middle 
(9.4≤ NAG/C <19.2, n = 29), and highest tertile of NAG/C (NAG/C ≤19.2, 
n = 29) were 4%, 28% and 52%, respectively (Figure 3). The difference 
was significant between lowest and highest tertile (p < 0.001) and not 
significant between lowest and middle tertile (p = 0.088). After adjustment 
for age, sex, serum albumin, baseline eGFR, blood pressure, and 
ACEi/ARB treatment, the multivariable adjusted hazard ratio of highest 
tertile of NAG/C was 18.97 (95% CI: 1.70, 211.86) compared to lowest 
tertile (Table S2). The remission rate evaluated in 72 patients with baseline 
NS was 79%, 56% and 29% in lowest, middle and highest tertile, 
respectively (Figure S2). The difference was significant between lowest 
and highest tertile (p = 0.002) and not significant between lowest and 
middle tertile (p = 0.35). Thus the NAG/C highest tertile showed 
significantly higher progression and lower remission rate compared to 
lowest tertile.   
                Functional outcome (progression, remission) according to 
tertiles of eGFR in all 86 patients.                
               The progression rate of lowest (eGFR <59, n = 28), middle (59≤ 
eGFR <88, n = 29), and highest tertile of eGFR (eGFR ≤88, n = 29) were 
61%, 17% and 7%, respectively (Figure 4). Compared to highest tertile 
group, lowest tertile had significantly higher progression rate (p < 0.001) 
and no significant difference was observed for middle tertile (p = 0.16). 
After adjustement for age, sex, serum albumin, NAG/C, blood pressure, 
and ACEi/ARB treatment, the hazard ratio of lowest tertile of eGFR (<59) 
was 11.58 (95%CI: 2.02, 66.29) compared to highest tertile (Table S2). 
The remission rate evaluated in 72 patients with baseline NS was 26%, 
61% and 67%, respectively (Figure S3). The difference was significant 
between highest and lowest tertile (p = 0.009) and not significant between 
highest and middle tertile (p = 0.74). Thus the lowest eGFR tertile showed 
higher progression and lower remission rate compared to highest tertile. 
               Risk stratification 
               A risk stratification in two groups was defined by combination of 
middle and highest tertiles of eGFR (≥59) and lowest and middle tertiles of 
NAG/C (<19.2) (low risk, n = 43) and highest tertile of NAG/C (≤19.2) or 
lowest tertile of eGFR (<59) (high risk, n = 43). Compared to low risk 
subjects, high risk subjects had significantly higher progression rate for 
those with and without NS (Figure S1). For NS subjects, the multivariable-
adjusted HR of progression for high risk group were 8.62 (95% CI 1.93, 
38.45, p = 0.005) compared to low risk group. 
                 Comparison between 30 NS patients IS-untreated (IS-) and 
35 NS patients treated with steroids and cyclophosphamide (IS+) 
according to low and high risk. 
                  In low risk patients both progression and remission rates were 
not significantly different between IS- (n = 19) and IS+ patients (n = 11): 
progression: 7% vs. 18%, respectively (p = 0.81); remission 75% vs. 73%, 
respectively (p = 0.39). In high risk patients both progression and 
remission rates were significantly different between IS- (n = 11) vs. IS+ (n 
= 24): progression 91% vs. 29% (p = 0.003); remission 0% vs. 42% (p < 
0.001) (Figure 5, Figure S4). The multivariable-adjusted HR of 
progression for IS+ was 0.09 (95% CI 0.02, 0.45, p = 0.003) compared to 
IS-. Noteworthy were the following observations: in 24 high risk IS+ 
patients 14 (58%) were unresponsive to treatment: 7 with progression and 
7 with persistent nephrotic syndrome with CRF; moreover of 10 high risk 
patients attaining remission 3 had baseline eGFR <59, while in IS- high 
risk patients none of them with baseline eGFR <59 attained remission. 
                 Change of renal function and proteinuria during follow-up 
period. 
                    In the highest tertile of NAG/C, the median change of eGFR 
during follow-up period in subjects without IS treatment was -9.1 
ml/min/1.73m2/year (25th, 75th percentile -13.0, -7.2) and those with 
steroids + cyclophosphamide treated was -0.9 ml/min/1.73m2/year (-2.6, 
+1.0), which was significantly smaller compared to no-IS subjects (p < 
0.001) (Table 4). In moderate to lowest tertile of eGFR, the median change 
of eGFR in no-IS was -7.8 (-10.1, -4.6) and -4.0 (-12.8, -0.5), and those 
with steroids + cyclophosphamide was -1.3 (-4.8, +0.2) and 0.0 (-2.6, 
+2.0), which was also significantly smaller compared to no-IS subjects (p 
= 0.014 and 0.038, respectively). The change of proteinuria during the 
follow-up period in subjects with Steroids + CY were significantly larger 
compared to those without IS treatments in the moderate eGFR (59≤ eGFR 
<88) group.  
  In the sensitivity analysis with an outcome as incident ESRD, no 
substantial changes to the result were seen (Data not shown).                   
              Discussion                                                                                              
               In a long follow-up study of 86 IMN subjects, the risk of 
progression was evaluated for eight baseline urinary markers and renal 
function. We found that NAG/C and eGFR were independent predictors of 
progression in both NS and non-NS subjects and allow in combination 
reliable risk stratification. By risk stratification analysis, high risk NS 
subjects with IS treatment had significantly lower progression and higher 
remission rate compared to those without IS treatment. In low risk group 
there were no significant differences for progression and remission rate 
between untreated and IS-treated subjects.  A recent review of 1.762 IMN 
patients from 36 randomized controlled trials (20) did not reach definitive 
conclusions about treatment; combination of steroids and 
cyclophosphamide appears as the most effective therapy, but is associated 
with rather high rate of serious adverse events. Recently RTX has been 
suggested as first line therapy of IMN with NS (13). The superior efficacy 
of RTX is suggested by its specific pathogenetic mechanism (depletion of 
B cells responsible of anti-PLA2R antibodies production) and by induction 
of remission also in patients unresponsive to other immuno-suppressive 
agents. The high rate of spontaneous remission (about 30-40%) in IMN 
patients with NS underlines the importance of availability of baseline risk 
stratification able to identify patient candidates to spontaneous remission 
and long-lasting NRF for whom supportive therapy is indicated and 
patients at high risk of progression for whom immuno-suppressive 
treatment should the first line therapy ideally started at diagnosis and not 
later in the disease course. A reliable outcome predictor should be based 
on pathophysiological progression mechanisms and able to predict 
remission prior to the start of treatment. As well known, proteinuria  play  
a central role in glomerulonephritis (GN) as marker of disease severity, 
factor responsible of further renal damage at glomerular and tubulo-
interstitial level (review in 21-24) and outcome predictor; moreover 
proteinuria reduction by RAS inhibition is associated with lowering of 
progression to renal failure and improvement of kidney survival (25). It 
has been demonstrated that tubulo-interstitial damage is also associated 
with chronic hypoxia (26). Several studies showed that high and low 
molecular weight (MW) proteins (IgG, IgM, α2-macroglobulin, α1-
microglobulin, β2-microglobulin) and the lysosomal enzyme NAG have a 
higher predictive value than albumin/creatinine ratio in various types of 
primary GN and Diabetic Nephropathy (27-43). Our risk stratification is 
based on very simple biomarkers such as the tubular damage marker 
urinary NAG/C and eGFR in combination.  NAG is a lysosomal enzyme 
of 130 kDa molecular mass normally excreted in urine in low amounts as a 
consequence of the normal exocytosis process (16,43); its urinary 
excretion increases after exposure to several tubulo-toxic substances and in 
various renal diseases; in glomerular diseases the analysis of NAG 
isoenzymes showed that the increased urinary excretion is due to an 
increased release by the renal tubular cells and not to increased filtration 
across the damaged GFB. Thus NAG excretion is universally recognized 
as a marker of functional and/or structural damage of tubular cells. In a 
study of 136 patients with IMN, Focal Segmental Glomerulosclerosis 
(FSGS) and Minimal Change Disease (16) NAG/C showed a significant 
relationship with 24-hour proteinuria and excretion of IgG and α1m; in NS 
patients with NRF NAG/C below or above selected cut-offs significantly 
predicted remission and progression to ESRD.    
The rational for suggestion of immunosuppressive treatment at diagnosis 
on the basis NAG/C and eGFR risk stratification is based on the 
observation that high NAG/C or low eGFR NS subjects without 
immunosuppressive treatment had median renal function decline of -7.8 to 
-9.1 ml/min/1.73m2/year, which was significantly larger compared to 
immunosuppressive treated subjects. Thus high risk subjects are suggested 
for immunosuppressive treatments at diagnosis to preserve renal function, 
since they are likely to progress during the observational period as 
recommended in the current guideline (14). In the high risk IS+ patients 
progression was significantly lower than in IS- patients (29% vs. 91%, p = 
0.003) and remission significantly higher (42% vs. 0%, p < 0.001), but 
58% of high risk IS+ patients were unresponsive to steroid and 
cyclophosphamide (7 progressors and 7 with persistent nephrotic 
syndrome after 89±71 months from starting therapy); thus an immuno-
suppressive treatment more effective than steroid and cyclophosphamide is 
warranted. The low risk IS- patients are characterized by 75% of remission 
and 84% of long-lasting  NRF  not significantly different from the IS+ 
patients (73% remission and 82% long-lasting renal function, 
respectively); thus low risk patients could be considered candidates to 
supportive therapy unless severe NS is present at risk of complications. On 
the basis of our data that reliably identify low and high risk patients may 
be rational the proposal of supportive therapy for low risk subjects and 
Rituximab as first-line therapy at diagnosis and not later after 
unresponsiveness to other treatments for high risk patients as more 
specific, safer and effective agent also in patients unresponsive to other 
non-specific treatments often associated with serious adverse events.   
                 Conclusions 
               The risk stratification based on urinary NAG/C and eGFR, 
markers of pathophysiological progression mechanisms, is very simple, 
low costly and readily available in clinical practice and may be a reliable 
criterion to identify at diagnosis the IMN patients with high probability of  
remission and long-lasting NRF or at risk of progression and thus may be  
a useful tool for early therapeutic decisions and selection of patients which 
should be treated with supportive therapy or with RTX as first-line therapy 
at diagnosis and not later after unresponsiveness to other treatments. 
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LEGENDS FOR TABLES AND FIGURES 
Table 1. Baseline characteristics of study subjects (n = 86) 
Age, serum albumin, and baseline eGFR are mean (SD). Male, BP, and ACEi treatments are subject 
numbers (percentage). Urinary markers are geometric means (95% confidence interval). Follow-up 
are median (range). 
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; UP/C, total urinary 
proteins/1 g urinary creatinine; α1m/C, urinary α1-microglobulin/1 g urinary creatinine;  NAG/C, 
urinary N-acetyl-β-glucosaminidase/1 g urinary creatinine;  α2m/C, urinary α2-macroglobulin/1 g 
urinary creatinine; Tf/C, serum Transferrin/1 g urinary creatinine; IgG/C, urinary IgG/1 g urinary 
creatinine; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor; SD, 
standard deviation. 
 
Table 2. Area under the receiver operating characteristic curves for prediction of progression 
by urinary markers 
(A) Proteinuria, UP/C, α1m/C, NAG/C, Tf/C, and IgG/C (n = 86). (B) Proteinuria and α2m/C (n = 
45). 
Abbreviations: UP/C, total urinary proteins/g urinary creatinine; α1m/C, urinary α1-microglobulin/g 
urinary creatinine;  NAG/C, urinary N-acetyl-β-glucosaminidase/g urinary creatinine; Tf/C, serum 
Transferrin/g urinary creatinine; IgG/C, urinary IgG/g urinary creatinine;  α2m/C, urinary α2-
macroglobulin/g urinary creatinine. 
 
Table 3. Unadjusted and multivariable-adjusted hazard ratio for progression (n = 86) 
*Adjusted for age, sex, serum albumin, baseline eGFR, blood pressure, and ACE inhibitor treatment.  
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; UP/C, total urinary 
proteins/g urinary creatinine; α1m/C, urinary α1-microglobulin/g urinary creatinine;  NAG/C, 
urinary N-acetyl-β-glucosaminidase/g urinary creatinine;  α2m/C, urinary α2-macroglobulin/g 
urinary creatinine; Tf/C, serum Transferrin/g urinary creatinine; IgG/C, urinary IgG/g urinary 
creatinine; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker. 
 
Table 4. Median (25th, 75th percentile) of eGFR changes (ml/min/1.73m2/year) by nephrotic 
syndrome and treatment according to tertiles of NAG/C or eGFR (n = 86) 
eGFR change = [eGFR(last) - eGFR(1st)]/Follow-up × 12 
Abbreviations: NAG/C, urinary N-acetyl-β-glucosaminidase/1 g urinary creatinine; eGFR, 
estimated glomerular filtration rate. 
 
Figure 1. Flow charts of study subjects for the analysis (n = 86) 
 
Figure 2. Receiver Operating Characteristic curves for prediction of progression by urinary 
markers 
(A) Proteinuria, UP/C, α1m/C, NAG/C, Tf/C, IgG/C (n = 86). (B) Proteinuria, α2m/C (n = 45). 
Abbreviations: UP/C, total urinary proteins/g urinary creatinine; α1m/C, urinary α1-microglobulin/g 
urinary creatinine;  NAG/C, urinary N-acetyl-β-glucosaminidase/g urinary creatinine; Tf/C, serum 
Transferrin/g urinary creatinine; IgG/C, urinary IgG/g urinary creatinine;  α2m/C, urinary α2-
macroglobulin/g urinary creatinine. 
 
Figure 3. Kaplan–Meier curves for the percentages of subjects with progression tertiles of 
NAG/C (n = 86) 
Abbreviation: NAG/C, urinary N-acetyl-β-glucosaminidase/g urinary creatinine. 
 
Figure 4. Kaplan–Meier curves for the percentages of subjects with progression by tertiles of 
eGFR (n = 86) 
Abbreviation: eGFR, estimated glomerular filtration rate. 
 
Figure 5. Kaplan–Meier curves for the percentages of subjects with progression with or 
without immunosuppressive treatment in low and high risk nephrotic syndrome subjects (n = 
65) 
(A) Low risk (NAG/C <19.2 and 59≤ eGFR) nephrotic syndrome subjects (n = 30). (B) High risk 
(19.2≤ NAG/C or eGFR <59) nephrotic syndrome subjects (n = 35). 
Abbreviations: NAG/C, urinary N-acetyl-β-glucosaminidase/g urinary creatinine; eGFR, estimated 
glomerular filtration rate; IS, immunosuppressive treatment; CY, Cyclophosphamide.
Table 1. Baseline characteristics of study subjects (n = 86) 
  
All 
  Nephrotic Syndrome 
 
(-) 
(+) 
 No 
Immunosuppressive 
treatment 
Steroids + 
Cyclophosphamide 
Steroids only 
  (n = 86)  (n = 14) (n = 30) (n = 35) (n = 7) 
Age, years 52 (17)  42 (18) 51 (18) 56 (17) 53 (14) 
Male, n (%) 50 (58)  7 (50) 13 (43) 26 (74) 4 (57) 
BP≥140/90mmHg, n (%) 47 (55)  7 (50) 15 (50) 19 (54) 6 (86) 
Serum Albumin, g/dL 2.6 (0.7)  3.6 (0.5) 2.5 (0.5) 2.3 (0.7) 2.7 (0.3) 
Baseline eGFR, ml/min/1.73m2 72 (29)  72 (40) 78 (27) 67 (24) 63 (35) 
Proteinuria, g/24h 4.4 (3.6, 5.3)  1.2 (0.7, 1.9) 5.0 (4.2, 6.0) 6.1 (5.1, 7.5) 5.8 (4.0, 8.6) 
UP/C, mg/gCre 2835 (2334, 3442)  1041 (571, 1898) 3451 (2622, 4541) 3581 (2864, 4476) 2810 (1755, 4500) 
Alb/C, mg/gCre 2302 (1837, 2885)  688 (289, 1639) 2781 (2124, 3640) 3180 (2571, 3934) 2281 (1525, 3411) 
α1m/C, mg/gCre 28.0 (22.3, 35.1)  16.3 (8.4, 31.5) 26.6 (18.1, 39.2) 36.2 (27.2, 48.0) 28.4 (13.0, 62.0) 
NAG/C, UI/gCre 11.8 (9.8, 14.3)  4.7 (2.7, 8.1) 15.1 (12.1, 18.9) 14.8 (11.2, 19.6) 8.6 (5.9, 12.4) 
α2m/C, mg/gCre (n = 45) 8.85 (6.77, 11.58)  1.81 (1.46, 2.24) 9.19 (5.83, 14.48) 9.57 (6.88, 13.32) 11.23 (4.58, 27.57) 
IgG/C, mg/gCre 116 (90, 150)  49 (28, 86) 128 (87, 187) 160 (110, 232) 93 (34, 253) 
Tf/C, mg/gCre 175 (137, 222)  47 (20, 108) 223 (164, 303) 239 (187, 304) 181 (110, 299) 
Selectivity Index (IgG/TF, n = 
85) 
0.19 (0.17, 0.21)  0.20 (0.16, 0.26) 0.18 (0.15, 0.22) 0.20 (0.17, 0.23) 0.18 (0.12, 0.24) 
ACEi/ARB treatments, n (%) 43 (50)  5 (36) 12 (40) 25 (71) 1 (14) 
Follow-up (months) 69 (6, 253)  48 (6, 143) 61 (12, 217) 97 (13, 253) 53 (24, 170) 
Age, serum albumin, and baseline eGFR are mean (SD). Male, BP, and ACEi/ARB treatments are subject numbers (percentage). Urinary markers 
are geometric means (95% confidence interval). Follow-up are median (range).  
Table 2. Area under the receiver operating characteristic curves for prediction of progression by urinary markers 
A. (n = 86) 
  Area Under Curve 95% CI P 
Proteinuria 0.637 (0.509, 0.765) - 
UP/C 0.748 (0.626, 0.870) 0.012 
Alb/C 0.733 (0.605, 0.862) 0.034 
α1m/C 0.785 (0.685, 0.886) 0.021 
NAG/C 0.770 (0.668, 0.860) 0.018 
IgG/C 0.754 (0.649, 0.860) 0.051 
Tf/C 0.702 (0.570, 0.835) 0.20 
 
B. (n=45) 
  Area Under Curve 95% CI P 
Proteinuria 0.600 (0.425, 0.775) - 
α2m/C 0.526 (0.337, 0.715) 0.37 
 
  
Table 3. Unadjusted and multivariable-adjusted hazard ratio for progression (n = 86) 
  Hazard Ratio 
  Unadjusted (95% CI) p  Multivariable-adjusted* (95% CI) p 
Age, years 1.03 (1.00, 1.05) 0.023  0.98 (0.94, 1.01) 0.10 
Male vs. Female 1.03 (0.46, 2.34) 0.94  0.64 (0.27, 1.56) 0.33 
Serum Albumin, g/dL 0.77 (0.43, 1.37) 0.37  0.49 (0.25, 0.97) 0.039 
Baseline eGFR, ml/min/1.73m2 0.97 (0.95, 0.98) <0.001  0.96 (0.94, 0.98) < 0.001 
BP≥140/90mmHg 3.88 (1.52, 9.86) 0.004  2.54 (0.62, 10.36) 0.19 
ACEi/ARB treatments 0.30 (0.13, 0.72) 0.007  0.23 (0.09, 0.57) 0.002 
        Proteinuria×10 2.28 (0.53, 9.85) 0.27  1.08 (0.15, 7.86) 0.11 
UP/C×10 14.65 (2.36, 91.02) 0.004  4.71 (0.79, 28.12) 0.089 
Alb/C×10 11.36 (1.73, 74.59) 0.011  3.95 (0.75, 20.90) 0.11 
α1m/C×10 10.41 (3.36, 32.28) <0.001  2.29 (0.45, 11.70) 0.32 
NAG/C×10 16.98 (3.21, 89.77) 0.001  20.98 (2.70, 162.69) 0.004 
IgG/C×10 5.85 (2.17, 15.77) <0.001  1.86 (0.50, 6.97) 0.36 
Tf/C×10 6.17 (1.32, 28.93) 0.021  2.80 (0.70, 11.23) 0.15 
α2m/C×10 1.48 (0.37, 5.84) 0.57  0.14 (0.02, 1.13) 0.065 
* Adjusted for age, sex, serum albumin, baseline eGFR, blood pressure, and ACEi/ARB treatment. 
  
Table 4. Median (25th, 75th percentile) of eGFR changes (ml/min/1.73m2/year) by nephrotic syndrome and treatment according to tertiles of 
NAG/C or eGFR (n = 86) 
  Nephrotic Syndrome  No Immunosuppressive 
treatment  vs. Steroids 
+ Cyclophosphamide 
p 
 
(-) 
(+) 
 
 No Immunosuppressive 
treatment 
Steroids + 
Cyclophosphamide 
Steroids only 
  
  (n = 14) (n = 30) (n = 35) (n = 7)   
NAG/C <9.4 -0.7 (-2.0, +3.6) -3.0 (-3.7, -1.2) -0.1 (-3.7, +0.4) -0.7 (-4.2, +1.9)  0.48 
9.4≤ NAG/C <19.2 -6.4 (-11.0, -1.0) -1.7 (-3.6, 0.0) -0.7 (-4.0, +0.4) +0.7 (-0.01, +1.5)  0.66 
19.2≤ NAG/C -2.0 -9.1 (-13.0, -7.2) -0.9 (-2.6, +1.0) +0.8  < 0.001 
       eGFR <59 -2.0 (-11.1, -1.8) -7.8 (-10.1, -4.6) -1.3 (-4.8, +0.2) +0.8 (-0.1, +1.5)  0.014 
59≤ eGFR <88 +16.0 -4.0 (-12.8, -0.5) 0.0 (-2.6, +2.0) -1.6 (-6.8, +3.5)  0.038 
88≤ eGFR -1.0 (-2.0, +1.6) -1.9 (-3.3, -1.2) -0.9 (-4.0, +0.2) -0.7 (-1.6, +0.2)  0.69 
eGFR change = [eGFR(last) - eGFR(1st)]/Follow-up × 12 
  
  
 
  
LEGENDS FOR SUPPLEMENTARY TABLES AND FIGURES 
Table S1. Number of subjects by renal function and clinical remission status at last 
observation (n = 86) 
Progression: ESRD or eGFR reduction ≥50% of baseline value. 
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease. 
 
Table S2. Multivariable-adjusted hazard ratio for progression by tertiles of NAG/C or eGFR 
(n = 86) 
a) Adjusted for age, sex, serum albumin, baseline eGFR, blood pressure, and ACEi/ARB treatment. 
b) Adjusted for age, sex, serum albumin, NAG/C, blood pressure, and ACEi/ARB treatment. 
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; UP/C, total urinary 
proteins/1 g urinary creatinine; α1m/C, urinary α1-microglobulin/1 g urinary creatinine;  NAG/C, 
urinary N-acetyl-β-glucosaminidase/1 g urinary creatinine;  α2m/C, urinary α2-macroglobulin/1 g 
urinary creatinine; Tf/C, serum Transferrin/1 g urinary creatinine; IgG/C, urinary IgG/1 g urinary 
creatinine; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker. 
 
Table S3. Median (25th, 75th percentile) of proteinuria changes (g/24h) of subjects with 
nephrotic syndrome by treatments according to tertiles of NAG/C or eGFR (n = 72) 
Proteinuria change = Proteinuria(last) – Proteinuria(1st) 
Abbreviations: NAG/C, urinary N-acetyl-β-glucosaminidase/1 g urinary creatinine; eGFR, 
estimated glomerular filtration rate. 
 
Figure S1. Kaplan–Meier curves for the percentages of subjects with progression with and 
without nephrotic syndrome (n=86) 
(A) Subjects without nephrotic syndrome (n=14). (B) Subjects with nephrotic syndrome (n=72). 
 
Figure S2. Kaplan–Meier curves for the percentages of nephrotic syndrome subjects with 
clinical remission by tertiles of NAG/C (n= 72) 
Abbreviation: NAG/C, urinary N-acetyl-β-glucosaminidase/1 g urinary creatinine. 
 
Figure S3. Kaplan–Meier curves for the percentages of nephrotic syndrome subjects with 
clinical remission by tertiles of eGFR (n = 72) 
Abbreviation: eGFR, estimated glomerular filtration rate. 
 
Figure S4. Kaplan–Meier curves for the percentages of subjects with clinical remission with 
or without immunosuppressive treatment in low and high risk nephrotic syndrome subjects (n 
= 65)  
(A) Low risk (NAG/C<19.2 and 59≤eGFR) nephrotic syndrome subjects (n = 30). (B) High risk 
(19.2≤NAG/C or eGFR<59) nephrotic syndrome subjects (n = 35) 
Abbreviations: NAG/C, urinary N-acetyl-β-glucosaminidase/1 g urinary creatinine; eGFR, 
estimated glomerular filtration rate; IS, immunosuppressive treatment; CY, Cyclophosphamide. 
Table S1. Number of subjects by renal function and clinical remission status at last observation (n = 86) 
Last observation                                                                                       
Nephrotic  Syndrome at baseline 
(-) 
(+) 
No 
Immunosuppressive 
treatment 
Steroids + 
Cyclophosphamide 
Steroids only 
(n = 14) (n = 30) (n = 35) (n = 7) 
n. of subjects (%) 
Normal renal function  (eGFR ≥60)                                                                                                                                                                                 9 (64)
 Clinical remission (+)                         14 (47) 14(40) 2 (29) 
 Clinical remission (-)  2 (7) 5 (14) 1 (14) 
Chronic renal failure (15< eGFR <60)                                                                                                                                                                             1(7) 
 Clinical remission (+)  0 (0) 4 (11) 3 (43) 
 Clinical remission (-)     6 (20) 5 (14) 1 (14) 
End-stage renal disease (eGFR ≤15) 4 (29) 8 (27) 7 (20) 0 (0) 
eGFR reduction ≥50% of baseline 2 (14) 10 (33) 9 (26) 0 (0) 
     
Progression 4(29) 11 (37) 9 (26) 0 (0) 
Progression: ESRD or eGFR reduction ≥50% of baseline value. 
  
Table S2. Multivariable-adjusted Hazard Ratio for progression by tertiles of NAG/C or eGFR (n = 86) 
  Hazard Ratio (95% CI) p 
NAG/C <9.4 1.00 (reference) - - 
9.4≤ NAG/C <19.2a) 9.81 (0.97, 99.60) 0.053 
19.2≤NAG/Ca) 18.97 (1.70, 211.86) 0.017 
    eGFR<59b) 11.58 (2.02, 66.29) 0.006 
59≤eGFR<88b) 2.77 (0.39, 19.41) 0.31 
88≤ eGFR 1.00 (reference) - - 
a) Adjusted for age, sex, serum albumin, baseline eGFR, blood pressure, and ACEi/ARB treatment. 
b) Adjusted for age, sex, serum albumin, NAG/C, blood pressure, and ACEi/ARB treatment. 
Table S3. Median (25th, 75th percentile) of proteinuria changes (g/24hr) of subjects with nephrotic syndrome by treatment according to tertiles of 
NAG/C or eGFR (n = 72) 
  
Nephrotic Syndrome  
No Immunosuppressive 
treatment  vs. Steroids + 
Cyclophosphamide 
p 
 No Immunosuppressive 
treatment 
Steroids + 
Cyclophosphamide 
Steroids only   
  (n = 30) (n = 34) (n = 7)   
NAG/C <9.4 -2.2 (-3.8, -1.0) -3.3 (-3.9, -3.1) -1.9 (-4.3, +1.9)  0.29 
9.4≤ NAG/C <19.2 -4.0 (-4.9, -1.5) -2.5 (-3.1, -0.4) -8.7 (-9.3, -8.0)  0.43 
19.2≤ NAG/C -1.6 (-3.7, -0.1) -5.1 (-7.9, -3.2) -10.5  0.060 
      eGFR <59 -1.6 (-3.4, -0.6) -2.9 (-3.3, -1.1) -9.3 (-10.5, -8.0)  0.56 
59≤ eGFR <88 -2.9 (-3.8, +2.9) -5.1 (-8.1, -3.4) +0.2 (-3.6, +4.0)  0.022 
88≤ eGFR -4.0 (-5.7, -1.5) -3.4 (-4.5, -3.1) -2.6 (-5.0, -0.2)  0.76 
Proteinuria change = Proteinuria(last) – Proteinuria(1st)
   
 
  
 
